It is shown that the transcriptional cofactor LBH drives mutation-independent Wnt activation and malignant progression in GC via a tumour microenvironment-regulated post-translational stabilization mechanism, elucidate a critical tumour–stroma crosstalk mechanism and establish the targeted disruption of the LBH–β-catenin interaction interface as a clinically relevant therapeutic strategy for advanced gastric cancer.
Abstract
Aberrant Wnt/β-catenin signaling is frequently observed in gastric cancer (GC); however, the mechanisms sustaining this pathway in the absence of canonical genetic mutations remain incompletely understood. Here we show that the transcriptional cofactor LBH drives mutation-independent Wnt activation and malignant progression in GC via a tumour microenvironment-regulated post-translational stabilization mechanism. By integrating single-cell transcriptomics with multicentre clinical cohorts, we identify LBH as a principal regulator of epithelial–mesenchymal transition and peritoneal metastasis, and its elevated expression independently predicts poor patient survival. Mechanistically, fi broblast activation protein (FAP)-positive cancer-associated fi broblasts (CAFs) secrete TGF-β1, which selectively induces LBH expression in adjacent GC cells via the SMAD2/3 signaling cascade. Crucially, LBH physically interacts with β-catenin, providing steric hindrance that prevents destruction complex-mediated phosphorylation and subsequent ubiquitin-proteasomal degradation. This FAP⁺ CAF–TGF-β1–LBH–β-catenin paracrine axis continuously sustains global Wnt transcriptional output without requiring intrinsic genetic mutations. Our findings elucidate a critical tumour–stroma crosstalk mechanism and establish the targeted disruption of the LBH–β-catenin interaction interface as a clinically relevant therapeutic strategy for advanced gastric cancer.
Findings identify a novel PRDX1-PRMT5 axis that activates Wnt/β-catenin signaling, highlighting a potential therapeutic strategy for CRC by targeting this pathway to suppress tumor progression and remodel the immune microenvironment.
Nianhua Yu, Xi Li, Jin-Li Han et al.· International Journal of Bio...· 0 citations
Together, these studies emphasize that Wnt/ b -catenin signaling is controlled at multiple regulatory levels and cellular compartments, supporting context-speci c and biomarker-guided therapeutic strategies.
S. Patergnani, D. Buchsbaum, G. Piazza et al.· Frontiers in Oncology· 0 citations
Findings identify NFAT5 as a contributor to TGF-β-induced EMT and stemness-associated breast cancer progression through its interaction with β-catenin, highlighting NFAT5-associated transcriptional regulation as a potential therapeutic target in aggressive breast cancer.
Dal-Ah Kim, Sung-Yup Cho, Chor Ho Jo et al.· Cell Death & Disease· 0 citations
The TGF-β1/TWIST2/TPI1 signaling axis is defined as an important regulator of pathogenic fibroblast behavior and pro-fibrotic responses through transcriptional control of TPI1, highlighting its potential as a therapeutic target for IPF.
Jiawei Chen, Yu Li, Kai Fu et al.· Cellular Signalling· 0 citations
A CAF-TAGLN/HGF/c-MET/DDX5/CAV1 signaling cascade linking stromal activation to tumor-cell transcriptional reprogramming and CAF-tumor crosstalk within the TME is defined to identify TAGLN as a potential therapeutic vulnerability for microenvironment-directed intervention in GC.
Qiang Li, Jia-Ning Yang, Lu-Hong Cao et al.· Cancer Letters· 0 citations
The study findings suggest the use of combinatorial therapies using conventional agents, such as 5-FU, and inhibitors of this pathway, as a useful therapeutic strategy to treat patients with colorectal cancer.
D. A. A. Ramos, Daniela Filomena Tavares de Pina, A. C. M. Sousa-Squiavinato et al.· Molecular Biology Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.